Global Avian Influenza Drug Market, By Strain Type (H5N1, H5N6, H6N1, H7N4, H7N9, H9N2, H10N8), Treatment Type (Neuraminidase Inhibitors, Viral Vaccines), Route of Administration (Oral, Injectable), Application (Chicken, Turkey, Goose and Duck), Distribution Channel Type (Online Pharmacy, Direct Tenders, Retailers, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Avian Influenza Drug Market
The avian influenza drug market is expected to gain growth at a potential rate of 6.00% in the forecast period of 2021 to 2028. The emergence of drugs used in the treatment of risk associated with avian influenza viral infection is the factor responsible for the market growth.
Avian influenza also known as bird flu is a type of an infectious viral infection of birds. It is usually found in aquatic birds such as ducks and geese. It can highly affect wild and domesticated birds. It is rare in human but it can occasionally affect the humans because of the close contact of infected birds.
The rapid increase in the poultry farming industries across the world is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise, the awareness about treatment, rise in the prevalence of influenza and technological advancement are also predictable to enhance the avian influenza drug market growth. Furthermore, rise in government funding and high demand of chicken meat among the consumers are also projected to drive the market growth rate.
In addition, the rise in the public and private initiatives by the government as well as non-government organizations for research and development and strong presence of advanced research facilities and presence of leading pharmaceutical and biopharmaceutical companies are likely to create various new opportunities that will impact this avian influenza drug market growth in the forecast period of 2021 to 2028.
However, the effectual treatment is very less available owing to low prevalence of avian influenza viral disease worldwide and lack of knowledge about avian influenza are expected to act as major restraints towards the growth of the avian influenza drug market, whereas technical challenges for production novel the rapiescan challenge the growth of the target market in the above mentioned forecast period.
This avian influenza drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis on the avian influenza drug market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Avian Influenza Drug Market Scope and Market Size
The avian influenza drug market is segmented on the basis of strain type, treatment type, route of administration, application, distribution channel and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of strain type, the avian influenza drug market can be segmented into H5N1, H5N6, H6N1, H7N4, H7N9, H9N2 and H10N8.
- Based on treatment type, the avian influenza drug market can be segmented into neuraminidase inhibitors and viral vaccines. Neuraminidase inhibitors have further been segmented into oseltamivir and zanamivir. Viral vaccines have further been segmented as influenza virus vaccine.
- The route of administration segment of the avian influenza drug market can be segmented into oral and injectable.
- Based on application, the avian influenza drug market can be segmented into chicken, turkey and goose and duck.
- Based on distribution channel, the avian influenza drug market can be segmented into online pharmacy, direct tenders, retailers and others.
- On the basis of end user, the avian influenza drug market can be segmented into hospitals, homecare, specialty clinics and others.
Avian Influenza Drug Market Country Level Analysis
The avian influenza drug market is analyzed and market size information is provided by country by strain type, treatment type, route of administration, application, distribution channel and end user as referenced above.
The countries covered in the avian influenza drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the avian influenza drug market due to rise in the prevalence of sophisticated healthcare infrastructure and increase in the research and development activities by the pharmaceutical companies. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the rapid development in the health care infrastructure and rise in the disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The avian influenza drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Avian Influenza Drug Market Share Analysis
The avian influenza drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to avian influenza drug market.
The major players covered in the avian influenza drug market report are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Allergan, Novartis AG, Baxter, BIOCRYST PHARMACEUTICALS, INC., UNM Pharma Inc., CSL Limited, Emergent BioSolutions Inc., Novavax, Inc., Medigen Biotechnology Corp, BiondVax Pharmaceuticals Ltd., INOVIO Pharmaceuticals, Vaxart, Inc., Johnson & Johnson Services, Inc., SINOVAC,Boehringer Ingelheim International GmbH, Ceva, Zoetis and Qianyuanhao Biological Co., Ltd., among other domestic and global players. Avian influenza drug market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-